A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
about
Regulation of glucose homeostasis by GLP-1Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityNew perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersDPP4 in DiabetesAdverse Effects of GLP-1 Receptor AgonistsSomething old, something new and something very old: drugs for treating type 2 diabetesBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingAction and therapeutic potential of oxyntomodulinSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusEfficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic reviewResponse to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:25Environmental risk factors for pancreatic cancer: an update.The future role of gut hormones in the treatment of obesitySafety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemA prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.Metformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO SystemIncretin-based therapies in prediabetes: Current evidence and future perspectivesThe dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cellsUse of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.Q&A: insulin secretion and type 2 diabetes: why do β-cells fail?Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized PatientsLiraglutide for treating type 1 diabetes.The double trouble of metabolic diseases: the diabetes-cancer link.Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists.Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic TissuesRegional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.Preoperative use of incretins is associated with increased diabetes remission after RYGB surgery among patients taking insulin: a retrospective cohort analysis.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Effects of glucagon-like peptide-1 receptor agonists on renal functionSitagliptin use and thyroid cancer risk in patients with type 2 diabetes.
P2860
Q24563430-F7CC6F97-16E2-4E46-9032-C004A66D291AQ24568148-B851910E-544B-4B27-BDBF-8F883CD3E5E5Q26750746-C895F24E-4765-444A-B22B-FF870C5B01BEQ26752699-53473DB7-AA85-47C8-844C-8806F35031E1Q26765609-D3F8BF59-10B6-461B-A6E4-CD9461A57D91Q26777654-B13037DF-7746-473D-B142-0E15E8B3E27FQ26797335-7795854B-98D7-478E-8F98-39822CE9DBAAQ26801346-7EAB5A00-0D37-4F00-8ABA-B013B7292E19Q26865663-7D2021D5-F8C4-4EE1-9D72-6307EFFF02DBQ26992979-00E38E62-B438-4BD0-9861-6B8A5F62219BQ27025870-82B9942B-CE1B-4969-8AD5-16BB1D802DEBQ27027877-6341D20D-5D80-4425-8C33-4F5AF1753109Q28076726-70FFDEB6-7839-4DE7-8F27-FC5CD67E83A9Q28679307-799C11C0-2AD0-4E01-A5DE-207C086F1294Q30248417-A79CC48C-6AB4-420B-9282-48061035C087Q30357431-AD6F6D40-FE66-4FF6-AB71-53CA50B5FE92Q31167862-FB0A43F1-0376-488B-9099-CEC99C7CEAF2Q33734024-2E6F1E04-D630-428B-AEC3-D2CD8419867EQ34041974-5EC309A0-EC36-41A9-AFB3-A5643FE491F8Q34062829-4DE792C8-13C5-41F7-B3A8-C7A0900FEF79Q34543028-160519DE-0C13-4353-B3AD-A0048DC422B3Q34558740-356CDA2F-7B25-4800-BDB1-B4B3482C01DBQ34679569-A4C47393-1023-443F-A649-DA8ED5BD27F4Q34699191-C0DD9493-FDFC-4416-A4E7-B0ADE5E95E5AQ35022184-78FAE6C4-012C-4089-B9DF-618EB988A7CEQ35108666-57339572-EAB1-4458-B711-98F03E3AF028Q35538305-EB295513-A7D8-4EDB-9F71-058751CF70FFQ35619020-5ACE9C72-A36C-40FB-851E-574DC6A242E0Q35906506-CB78CE9E-758C-44B5-8E3B-32814F1D9ACBQ35912987-C1497DA5-B2E6-4CB3-8FDE-A0B0074DF8C9Q35939660-55FDAA01-FE58-441E-9D73-8CEC342BB609Q36058422-C0A3EFDC-3AF9-44E4-BC4C-0D4A505B0521Q36168227-238BF56C-F972-44A4-B573-63F2CD5872FCQ36327126-781228BE-C6A1-4977-8B44-2D431E99F069Q36665328-ED29B80D-6DF5-4895-AE35-91712600641FQ36926903-14AFC92F-AAEE-4CF2-B7A8-EAD2690C72C9Q36978258-91AB7D3A-18A9-4FE7-9FE8-80C8608D1F8CQ37193295-CE16A303-6318-454D-8CEE-04C73B0FB4C9Q37232679-A451B119-B5BC-40E3-B92F-C7F1AF283389Q37269476-EC881242-6F27-47AD-9573-A54058666821
P2860
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A critical analysis of the cli ...... Are the GLP-1 therapies safe?
@en
type
label
A critical analysis of the cli ...... Are the GLP-1 therapies safe?
@en
prefLabel
A critical analysis of the cli ...... Are the GLP-1 therapies safe?
@en
P2860
P356
P1433
P1476
A critical analysis of the cli ...... Are the GLP-1 therapies safe?
@en
P2093
Edwin A M Gale
Peter C Butler
P2860
P304
P356
10.2337/DC12-2713
P407
P577
2013-05-03T00:00:00Z